Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin vs Sitagliptin in T2DM with Systolic Heart Failure
NCT02920918Phase 4Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Oct 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of canagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Virginia Commonwealth University. Primary endpoints: Peak Oxygen Consumption at 12 weeks and Minute Ventilation/Carbon Dioxide Production Slope at 12 weeks. Started Oct 2016; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02920918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920918.